DNA polymorphisms and tissue cyclooxygenase-2 expression in oral lichen planus: A case-control study

Journal of the European Academy of Dermatology and Venereology

Volumn 26, Issue 9, 2012, Pages 1122-1126

  Abdel Hay, R M ^a   Fawzy, M M ^a   Metwally, D ^a   Kadry, D ^a   Ezzat, M ^a   Rashwan, W ^b   Rashed, L A ^a  

^a CAIRO UNIVERSITY   (Egypt)

^b MSA University   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; PROSTAGLANDIN E2;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; HUMAN; LICHEN PLANUS; MALE; MOUTH LICHEN PLANUS; ORAL MUCOSAL DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BASE SEQUENCE; CASE-CONTROL STUDIES; CYCLOOXYGENASE 2; DNA; DNA PRIMERS; HUMANS; LICHEN PLANUS, ORAL; POLYMORPHISM, GENETIC;

EID: 84865074908     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.04229.x     Document Type: Article

References (25)

1. Barnes L, Eveson JW, Reichart P, Sidransky D,. World Health Organization classification of tumours. Pathology and genetics, head and neck tumours. IARCPress, Lyon, 2005.
2. Lodi G, Scully C, Carrozzo M, et al. Current controversies in oral lichen planus: report of an international consensus meeting. Part 2. Clinical management and malignant transformation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005; 100: 164-178.
3. Neppelberg E, Johannessen AC,. DNA content, Cyclooxygenase-2 expression and loss of E-cadherin expression do not predict risk of malignant transformation in oral lichen planus. Eur Arch Otorhinolaryngol 2007; 264: 1223-1230.
4. Coussens LM, Werb Z,. Inflammation and cancer. Nature 2002; 420: 860-867.
5. Chan G, Boyle JO, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 1999; 59: 991-994.
6. Lin DT, Subbaramaiah K, Shah JP, et al. Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer. Head Neck 2002; 24: 792-799.
7. Shibata M, Kodani I, Osaki M, et al. Cyclo-oxygenase-1 and -2 expression in human oral mucosa, dysplasias and squamous cell carcinomas and their pathological significance. Oral Oncol 2005; 41: 304-312.
8. McAdam BF, Mardini IA, Habib A, et al. Effect of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation. J Clin Invest 2000; 105: 1473-1482.
9. Williams CS, Mann M, DuBois RN,. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999; 18: 7908-7916.
10. Trifan OC, Hla T,. Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis. J Cell Mol Med 2003; 7: 207-222.
11. Soslow RA, Dannenberg AJ, Rush D, et al. Cox-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 2000; 89: 2637-2645.
12. Koki AT, Masferrer JL,. Celecoxib: a specific COX-2 inhibitor with anticancer properties. Cancer Control 2002; 9: 28-35.
13. Tazawa R, Xu XM, Wu KK, Wang LH,. Characterization of the genomic structure, chromosomal location and promoter of human prostaglandin H synthase-2 gene. Biochem Biophys Res Commun 1994; 203: 190-199.
14. Papafili A, Hill MR, Brull DJ, et al. Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler Thromb Vasc Biol 2002; 22: 1631-1636.
15. Szczeklik W, Sanak M, Szczeklik A,. Functional effects and gender association of COX-2 gene polymorphism G-765C in bronchial asthma. J Allergy Clin Immunol 2004; 114: 248-253.
16. Zhang X, Miao X, Tan W, et al. Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology 2005; 129: 565-576.
17. Zhu W, Wei BB, Shan X, Liu P,. 765G>C and 8473T>C polymorphisms of COX-2 and cancer risk: a meta-analysis based on 33 case-control studies. Mol Biol Rep 2009; 37: 277-288.
18. AkkÄz H, Bayram S, Bekar A, et al. Functional polymorphisms of cyclooxygenase-2 gene and risk for hepatocellular carcinoma. Mol Cell Biochem 2011; 347: 201-208.
19. Canto AM, Müller H, Freitas RR, Santos PS,. Oral lichen planus (OLP): clinical and complementary diagnosis. An Bras Dermatol 2010; 85: 669-675.
20. Lin HP, Wang YP, Chia JS, Sun A,. Modulation of serum antinuclear antibody levels by levamisole treatment in patients with oral lichen planus. J Formos Med Assoc 2011; 110: 316-321.
21. Noguchi K, Shitashige M, Ishikawa I,. Involvement of cyclooxygenase-2 in interleukin-1alpha-induced prostaglandin production by human periodontal ligament cells. J Periodontol 1999; 70: 902-908.
22. Pinto S, Gallo O, Dilaghi M, et al. Prostaglandins in squamous cell carcinoma of the larynx: tumor and peritumor synthesis. Prostaglandins Leukot Essent Fatty Acids 1990; 39: 53-57.
23. Eisen D,. The clinical features, malignant potential, and systemic associations of oral lichen planus: a study of 723 patients. J Am Acad Dermatol 2002; 46: 207-214.
24. Lysitsa S, Samson J, Gerber-Wicht C, et al. COX-2 expression in oral lichen planus. Dermatology 2008; 217: 150-155.
25. Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K,. A comprehensive review of genetic association studies. Genet Med 2002; 4: 45-61.